Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology ...

An update from Nanjing Leads Biolabs Co., Ltd. Class H ( ($HK:9887) ) is now available. Nanjing Leads Biolabs Co., Ltd. announced that five of its ...

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, ...

The poster presentation will be available on the Aptose website here.